Compare Nu Holdings Ltd (NU) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nu Holdings Ltd vs Tango Therapeutics Inc. — how do they compare? Nu Holdings Ltd trades at $14.63 (market cap $75.26B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Nu Holdings Ltd is far larger — about 20.1× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Nu Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nu Holdings Ltd for 53 Days and Tango Therapeutics Inc. for 0 Days on average.
| NU | TNGX | |
|---|---|---|
Market Cap | $75.26B | $3.75B |
Volume | 60,119,584 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $18.76 | $32.90 |
52-Week Low | $11.60 | $7.50 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $97.88B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NU stock trades at $14.93, down 6.75% over 24 hours amid recent volatility. The technical outlook is bullish based on moving averages, though the 6-day RSI at 88.3 suggests overbought conditions. Fundamentally, the company shows strong growth with revenue rising from $3.0B in 2022 to $10.63B in 2025 and net income margin improving to 26.99%. Recent news includes denial of Monzo acquisition talks, causing price swings.
The outlook remains positive given robust fundamentals and analyst consensus, but risks include high valuation multiples, credit concentration, and acquisition speculation volatility. Upside to the $16.53 price target offers potential, though investor caution is warranted near technical resistance.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
